Neurogene
NGNE
82 hedge funds and large institutions have $249M invested in Neurogene in 2021 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 27 increasing their positions, 24 reducing their positions, and 9 closing their positions.
13% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 24
0% more funds holding
Funds holding: 82 → 82 (0)
0% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 9
0.1% less ownership
Funds ownership: 3.28% → 3.18% (-0.1%)
27% less capital invested
Capital invested by funds: $342M → $249M (-$93.1M)
64% less call options, than puts
Call options by funds: $703K | Put options by funds: $1.97M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$5.66M |
| 2 |
Morgan Stanley
New York
|
+$3.16M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$1.69M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$832K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$502K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$8.45M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.71M |
| 3 |
State Street
Boston,
Massachusetts
|
-$3.8M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$2.19M |
| 5 |
Goldman Sachs
New York
|
-$1.44M |
NGNE Hedge Fund Activity: Q2 2021 in Review
82 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Neurogene (NGNE) for Q2 2021, worth a combined $249M — down 27% from $342M a quarter earlier.
Fund positioning in NGNE was balanced in Q2 2021: 9 funds opened new positions, 9 closed out, 27 added to existing stakes and 24 trimmed.
The largest buyer was Candriam SCA, adding an estimated $5.66M. The largest seller was EcoR1 Capital, cutting an estimated $8.45M.
- 82 institutional investors held Neurogene (NGNE) as of Q2 2021, unchanged from Q1 2021.
- Funds reported $249M of Neurogene stock for Q2 2021, down 27% quarter-over-quarter.
- 9 funds opened new Neurogene positions in Q2 2021 and 9 closed out, a net change of 0 holders.
- The largest Neurogene buyer in Q2 2021 was Candriam SCA, an estimated $5.66M added.
- The largest Neurogene seller in Q2 2021 was EcoR1 Capital, an estimated $8.45M sold.
Based on aggregated 13F filings for Q2 2021.